



August 14, 2026

TO

BSE

NSE

Sub.: Approval of Proposal for Change of Name and Expansion of Main Objects to Include Medical Technology

Shukra Pharmaceuticals Limited ("Company") wishes to inform its shareholders, investors and other stakeholders that the Board of Directors of the Company, at its meeting held on **August 14, 2026**, has considered and approved, subject to the receipt of requisite statutory and regulatory approvals, the proposal for:

1. Change in the name of the Company from "Shukra Pharmaceuticals Limited" to "Shukra Medtech Limited", or such other name as may be approved by the Registrar of Companies and other competent authorities; and
2. Alteration and expansion of the existing Main Objects Clause of the Memorandum of Association of the Company to enable the Company to undertake activities in the field of Medical Technology (MedTech), including development, manufacturing, processing, designing, research and development, distribution, marketing, trading and related activities in medical technology products, devices, equipment, systems and solutions, subject to applicable laws and regulatory approvals.

The proposed change in name and expansion of the Main Objects are intended to provide the Company with a broader corporate identity and enable it to explore and undertake business opportunities in the medical technology sector, in addition to its existing pharmaceutical and healthcare-related activities.

The proposed alteration of the Memorandum of Association and change of name shall be subject to the approval of the shareholders of the Company and such other approvals, permissions, sanctions and filings as may be required under the applicable provisions of the Companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws and regulations.

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.


The Company will make further disclosures regarding the proposed change of name, alteration of the Main Objects Clause and the process for obtaining the requisite approvals, as and when applicable.

The above proposal is part of the Company's broader strategy to expand its presence across the healthcare and medical technology ecosystem and create opportunities for sustainable long-term growth.

For Shukra Pharmaceuticals Limited

**SHIVKANT
DHAKAD**

Digitally signed by SHIVKANT DHAKAD
DN: c=IN, postalCode=384006, st=GUJARAT,
PRIME 34, street=TEHIL, BARIL, GRAM - UNITYA
KALAN, RAJESHA, 606061, o=Personal,
serialNumber=00603434020353045723a33dcd3021
caltb44f09d22245e0235585210613002,
pseudoym=6147083031477885172e032cd302,
2.5.4.20=cd359f413a16708103450400a317c421340
f1070c9ebal341259780407c5,
email=SHIVKANTDHAKAD@SHUKRA.COM,
o=SHIVKANTDHAKAD,
Date: 2020.08.14 15:10:29 +05'30'



Name: Shivkant Dhakad

Designation: Company Secretary

Membership No.: A80894

CIN : L24231GJ1993PLC019079